跳至主要内容
临床试验/NCT02776397
NCT02776397Unknown不适用

Relationship of Haptoglobin Phenotype to Vascular Function and Response to Vitamin E Supplementation in Patients With Diabetes Mellitus Type 2: The EVAS Trial

Tan Tock Seng Hospital2 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2015年6月1日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
300
试验地点
2
主要终点
Endothelial function

研究概览

简要总结

Relationship of haptoglobin phenotype to vascular function and response to Vitamin E supplementation in Patients with Diabetes Mellitus Type 2: The EVAS Trial

Specific Aims:

The phenotype haptoglobin 2-2 (Hp 2-2) is associated with higher oxidative stress, inflammation, LDL peroxidation and higher cardiovascular risk in patients with diabetes. We aim to determine whether Hp 2-2 phenotype is associated with surrogate markers of cardiovascular risk, inflammation, lipids and lipoprotein profile, oxidative stress, and endothelial cell (EC) apoptosis (in vitro study) in patients with diabetes in our population and whether vitamin E supplementation mitigates this risk.

Methods:

Screening Phase:

We will recruit 300 patients with diabetes mellitus type 2 (100 Chinese, 100 Malays and 100 Indians) and assess their Hp phenotype, surrogate markers of cardiovascular risk, inflammation, vascular biomarkers and lipids phenotype.

In vitro Study:

Plasma from 20 patients with Hp 2-2 phenotype and 20 patients with non Hp 2-2 phenotype will be studied in vitro using a haemodynamic lab-on-chip system to determine whether there is a difference in EC apoptosis between the two groups.

Randomisation Phase 200 patients will be recruited to a pilot randomized controlled trial (RCT), stratified by Hp 2-2 phenotype status (100 Hp 2-2 and 100 non-Hp 2-2), and randomly allocated in a 1:1 ratio to either vitamin E 400 IU supplementation daily for 6 months or a placebo group. The trial will determine whether vitamin E improves the aforementioned surrogate markers in the Hp phenotype strata.

Importance of proposed research to science and medicine:

This study allows us to understand the possible mechanism of cardiovascular risk in patients with Hp 2-2 phenotype and to see whether vitamin E supplementation reduces this risk in a pharmacogenomic targeted manner.

详细描述

1.0 Background and Clinical Significance 1.1 Introduction The incidence of Diabetes Mellitus type 2 (DM2) is growing rapidly globally and in Singapore. The main cause of increased morbidity and mortality in patients with DM2 is the development of microvascular and macrovascular complications. Although strict glycaemic control has been proven to reduce microvascular complications, the evidence is still lacking with regards to macrovascular complications. Accelerated atherosclerosis is the leading cause of increased mortality and morbidity in these patients. It is of paramount importance to assess novel targets to control atherosclerosis in patients with DM2 on top of conventional treatment. There is an unmet need to find new targets or markers predicting increased risk in patients with diabetes mellitus and we need to consider alternative treatments on top of conventional targets to reduce risk in these high risk group patients.

Patients with DM2 are not only at an increased risk for atherosclerosis, they also carry a greater extent of the disease burden. Endothelial dysfunction is considered the hallmark of the pathological insult inflicted on the blood vessels. Hyperglycaemia affects mitochondrial, enzymatic, and non-enzymatic pathways associated with the generation of reactive oxygen species (ROS), leading to decreased nitric oxide bioavailability and endothelial dysfunction, commonly demonstrated by reduced endothelium dependent vasodilatation and increased plasma levels of endothelium derived regulatory proteins. Moreover, DM2 patients have compromised antioxidant defenses in the form of low levels of the antioxidant enzymes and alpha-tocopherol (vitamin E), which may impede an adequate compensation for the increase in oxidative stress. Another role of oxidative stress in mediating the development of atherosclerosis has also been demonstrated in the oxidative hypothesis. In this model the most prominent target for oxidative modification is the LDL molecule. Oxidised LDL is not recognized by the LDL receptor but is readily taken up by the CD36 scavenger receptor pathway in macrophages leading to appreciable cholesteryl ester accumulation and foam cell formation. Oxidized LDL is proinflammatory, it causes inhibition of endothelial NO synthetase, promotes vasoconstriction and monocyte adhesion, and promotes platelet aggregation and thrombosis.

Hp Phenotype and Oxidative Tissue Damage

The haptoglobin (Hp) protein is an antioxidant due to its ability to neutralize the oxidative activity of haemoglobin (Hb). In humans, Hp is characterised by a genetic polymorphism with three structurally different phenotypes (Hp1-1, Hp 2-1 and Hp 2-2 which result from expression of two different alleles (Hp 1 and Hp 2) of the haptoglobin gene located on chromosome 16q22. The protein product of the Hp2 allele is an inferior antioxidant compared to Hp1 allele product. Hp 1-1 is a small molecule (86kDa) of well-defined structure, whereas Hp 2-1 is characterised by heteropolymers (86-300 kDA) and Hp 2-2 forms large macromolecular complexes (170-1,000 kDa).

The function of Hp is to bind free Hb released from red blood cells, which is released into the blood during the natural turnover of red blood cells. Free Hb is capable of causing considerable oxidative tissue damage as a result of its heme iron. However, whenever Hb is released into the circulation it immediately binds to Hp with extremely high affinity to form an Hp-Hb complex. This binding serves to inhibit the oxidative potential of Hb by preventing the release of heme iron from Hb. Hp is normally found in the blood in a more than 400-fold molar excess to free Hb and therefore Hp is capable of binding all of the Hb that is released during normal red blood cell turnover. Once Hb is bound to Hp it is rapidly cleared from the blood stream via the CD163 scavenger receptor expressed on monocyte/macrophages, however, formation and clearance of Hp-Hb complexes are impaired in Hp 2-2 phenotypes.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
21 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Study patients should meet the following criteria for inclusion in the study:
  • 100 Chinese, 100 Malays, 100 Indian patients with DM2
  • Age 21-80 years
  • Able to give informed consent
  • Stable diabetes, blood pressure and hyperlipidaemia medications (a 25% dose adjustment is allowed) in the last three months
  • For eligibility to be randomized: HbA1c should be 10% inclusive or below at time of randomisation
  • Blood Pressure should be less than 180/120 mm Hg at time of recruitment
  • Non-smokers or discontinued smoking at least 6 months ago
  • No h/o previous myocardial infarction, previous cerebrovascular accident inclusive of haemorrhage and infarction, or h/o of peripheral amputation or bypass procedures

排除标准

  • Inability to give informed consent
  • Pregnant subjects
  • Patients hospitalized for any condition less than 1 month from enrolment
  • Patients having any recent infections or symptoms suggestive of any systemic infection in the last 2 weeks
  • Myocardial Infarction or stroke within 6 months before enrolment
  • Patients with creatinine concentrations >200 µmol/L or eGFR<30 µmol/L
  • Patients on anticoagulants such as warfarin
  • Known allergy to vitamin E
  • Current smokers
  • h/o previous myocardial infarction, previous cerebrovascular accident inclusive of haemorrhage and infarction, or h/o of peripheral amputation or bypass procedures
  • Patients on immunosuppressive agents or corticosteroids for other conditions
  • Presence of concomitant malignancies or rheumatological conditions at the time of recruitment
  • Patients taking orlistat & cholestyramine

结局指标

主要结局

Endothelial function

时间窗: 6 months

Measured as Reactive hyperemia index using RHI-EndoPAT

Aortic artery stiffness

时间窗: 6 months

Measured as pulse wave velocity using the sphygmocor device

Carotid Artery Intima Media Thickness

时间窗: 6 months

Measured as CIMT (average) in mm.

Inflammation

时间窗: 6 months

Measured as hs-CRP

Oxidative Stress

时间窗: 6 months

Measured as oxidative stress index

次要结局

  • Glycemic status(6 months)
  • Retinal arteriovenous index(6 months)
  • Non HDL-Cholesterol(6 months)

研究者

发起方
Tan Tock Seng Hospital
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验